中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 172-177

Influencing factors for the racial and ethnic disparities in metabolic associated fatty liver disease

DOI: 10.12449/JCH260121
  • 1.

    The First Clinical Medical College of Inner Mongolia Medical University，Hohhot 010030，China

  • 2.

    Department of Gastroenterology，The Affiliated Hospital of Inner Mongolia Medical University，Hohhot 010030，China

Research funding:

National Natural Science Foundation of China (82260115);

Natural Science Fund Project of Inner Mongolia Autonomous Region (2023QN08061);

Youth Exploration Project of Affiliated Hospital of Inner Mongolia Medical University (2023NYFYTS019)

More Information
  • Corresponding author: CHEN Ping， nmgcp@sina.com （ORCID： 0000-0003-2504-3659）
  • Received Date: 2025-04-29
  • Accepted Date: 2025-05-21
  • Published Date: 2026-01-25
    Abstract
  • Metabolic associated fatty liver disease （MAFLD） is a chronic liver disease closely associated with metabolic syndrome， characterized by a complex pathogenesis involving genetic， environmental， and lifestyle factors. Recent studies have shown significant disparities in the prevalence rate and clinical features of MAFLD across different racial and ethnic groups， and such disparities might be associated with various factors such as genetic background， environmental factors， socioeconomic disparities， and metabolic profiles. This article reviews the latest research advances in racial and ethnic differences in MAFLD in China and globally， discusses its potential pathogenic mechanisms and clinical significance， proposes future research directions and interventional measures， and emphasizes the critical need to enhance MAFLD screening and preventive health education in multiethnic populations.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta‑analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851‑ 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [2]
    KAN CX, ZHANG KX, WANG YQ, et al. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045[J]. Ann Hepatol, 2025, 30( 2): 101898. DOI: 10.1016/j.aohep.2025.101898.
    [3]
    TALENS M, TUMAS N, LAZARUS JV, et al. What do we know about inequalities in NAFLD distribution and outcomes? A scoping review[J]. J Clin Med, 2021, 10( 21): 5019. DOI: 10.3390/jcm10215019.
    [4]
    SHAHEEN M, SCHRODE KM, PAN DY, et al. Sex-specific differences in the association between race/ethnicity and NAFLD among US population[J]. Front Med, 2021, 8: 795421. DOI: 10.3389/fmed.2021.795421.
    [5]
    LE MH, YEO YH, CHEUNG R, et al. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016[J]. J Intern Med, 2020, 287( 6): 711- 722. DOI: 10.1111/joim.13035.
    [6]
    QAYED E, MIGDAL AL, JAGANNATHAN R, et al. Characteristics and outcomes of black and white patients hospitalized with nonalcoholic steatohepatitis: A nationwide analysis[J]. J Clin Gastroenterol, 2023, 57( 5): 508- 514. DOI: 10.1097/MCG.0000000000001698.
    [7]
    PINHEIRO PS, MEDINA HN, CALLAHAN KE, et al. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida[J]. Liver Int, 2020, 40( 5): 1201- 1210. DOI: 10.1111/liv.14409.
    [8]
    JIAO JJ, KWAN SY, SABOTTA CM, et al. Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in south Texas hispanics[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30( 9): 1643- 1651. DOI: 10.1158/1055-9965.EPI-21-0183.
    [9]
    MAZI TA, BORKOWSKI K, FIEHN O, et al. Plasma oxylipin profile discriminates ethnicities in subjects with non-alcoholic steatohepatitis: An exploratory analysis[J]. Metabolites, 2022, 12( 2): 192. DOI: 10.3390/metabo12020192.
    [10]
    KIM D, CHOLANKERIL G, AHMED A. Association between body fat distribution and nonalcoholic fatty liver disease/fibrosis based on race/ethnicity[J]. J Obes Metab Syndr, 2024, 33( 4): 326- 336. DOI: 10.7570/jomes24005.
    [11]
    AGBIM U, CARR RM, PICKETT-BLAKELY O, et al. Ethnic disparities in adiposity: Focus on non-alcoholic fatty liver disease, visceral, and generalized obesity[J]. Curr Obes Rep, 2019, 8( 3): 243- 254. DOI: 10.1007/s13679-019-00349-x.
    [12]
    LIN LM, LAI JM, LUO L, et al. Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated steatotic liver disease: A network meta-analysis[J]. Ann Hepatol, 2025, 30( 2): 101780. DOI: 10.1016/j.aohep.2025.101780.
    [13]
    BONACINI M, KASSAMALI F, KARI S, et al. Racial differences in prevalence and severity of non-alcoholic fatty liver disease[J]. World J Hepatol, 2021, 13( 7): 763- 773. DOI: 10.4254/wjh.v13.i7.763.
    [14]
    BRIL F, PORTILLO-SANCHEZ P, LIU IC, et al. Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients[J]. Diabetes Care, 2018, 41( 1): 187- 192. DOI: 10.2337/dc17-1349.
    [15]
    ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40( 12): 1461- 1465. DOI: 10.1038/ng.257.
    [16]
    LAU PP, WEI CY, LIN MR, et al. Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities[J]. Cell Biosci, 2025, 15( 1): 19. DOI: 10.1186/s13578-025-01346-5.
    [17]
    TING YW, KONG AS, ZAIN SM, et al. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort[J]. Clin Mol Hepatol, 2021, 27( 3): 486- 498. DOI: 10.3350/cmh.2020.0162.
    [18]
    ZAIN SM, MOHAMED Z, MAHADEVA S, et al. Susceptibility and gene interaction study of the angiotensin II type 1 receptor(AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population[J]. PLoS One, 2013, 8( 3): e58538. DOI: 10.1371/journal.pone.0058538.
    [19]
    CAVALCANTE LN, PORTO J, MAZO D, et al. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population[J]. Ann Hepatol, 2022, 27( 6): 100728. DOI: 10.1016/j.aohep.2022.100728.
    [20]
    MANCINA RM, DONGIOVANNI P, PETTA S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent[J]. Gastroenterology, 2016, 150( 5): 1219- 1230. e 6. DOI: 10.1053/j.gastro.2016.01.032.
    [21]
    BOONVISUT S, NAKAYAMA K, MAKISHIMA S, et al. Replication analysis of genetic association of the NCAN-CILP2 region with plasma lipid levels and non-alcoholic fatty liver disease in Asian and Pacific ethnic groups[J]. Lipids Health Dis, 2016, 15: 8. DOI: 10.1186/s12944-016-0181-z.
    [22]
    BAKER PR 2nd, FRIEDMAN JE. Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease[J]. J Clin Invest, 2018, 128( 9): 3692- 3703. DOI: 10.1172/JCI120846.
    [23]
    YE WR, SIWKO S, TSAI RYL. Sex and race-related DNA methylation changes in hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22( 8): 3820. DOI: 10.3390/ijms22083820.
    [24]
    LIN SL, XIAN YJ, LIU Y, et al. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China[J]. Medicine, 2018, 97( 9): e0021. DOI: 10.1097/MD.0000000000010021.
    [25]
    QUAN XH, YANG YH. Analysis of risk factors of nonalcoholic fatty liver in Mongolian population in Chifeng area[J]. China Foreign Med Treat, 2014, 33( 1): 135- 136. DOI: 10.16662/j.cnki.1674-0742.2014.01.065.

    全晓红, 杨艳红. 赤峰地区蒙古族人群非酒精性脂肪肝发病危险因素分析[J]. 中外医疗, 2014, 33( 1): 135- 136. DOI: 10.16662/j.cnki.1674-0742.2014.01.065.
    [26]
    SHAHEEN M, SCHRODE KM, TEDLOS M, et al. Racial/ethnic and gender disparity in the severity of NAFLD among people with diabetes or prediabetes[J]. Front Physiol, 2023, 14: 1076730. DOI: 10.3389/fphys.2023.1076730.
    [27]
    BROWNING MG, KHORAKI J, DEANTONIO JH, et al. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes[J]. Int J Obes, 2018, 42( 4): 926- 929. DOI: 10.1038/ijo.2017.309.
    [28]
    ZHAO Y, LI D, SHI HY, et al. Associations between type 2 diabetes mellitus and chronic liver diseases: Evidence from a Mendelian randomization study in Europeans and East Asians[J]. Front Endocrinol, 2024, 15: 1338465. DOI: 10.3389/fendo.2024.1338465.
    [29]
    GEURTSEN ML, WAHAB RJ, FELIX JF, et al. Maternal early-pregnancy glucose concentrations and liver fat among school-age children[J]. Hepatology, 2021, 74( 4): 1902- 1913. DOI: 10.1002/hep.31910.
    [30]
    KHOUDARY SR EL, SAMARGANDY S, ZEB I, et al. Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort[J]. Nutr Metab Cardiovasc Dis, 2020, 30( 1): 114- 122. DOI: 10.1016/j.numecd.2019.09.004.
    [31]
    YANG LD, HE H, AN ZM. Role of intestinal flora in metabolic-associated fatty liver disease[J]. J Clin Hepatol, 2021, 37( 9): 2231- 2235. DOI: 10.3969/j.issn.1001-5256.2021.09.046.

    杨礼丹, 何訸, 安振梅. 肠道菌群在代谢相关脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2021, 37( 9): 2231- 2235. DOI: 10.3969/j.issn.1001-5256.2021.09.046.
    [32]
    DESCHASAUX M, BOUTER KE, PRODAN A, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography[J]. Nat Med, 2018, 24( 10): 1526- 1531. DOI: 10.1038/s41591-018-0160-1.
    [33]
    HULLAR MAJ, JENKINS IC, RANDOLPH TW, et al. Associations of the gut microbiome with hepatic adiposity in the multiethnic cohort adiposity phenotype study[J]. Gut Microbes, 2021, 13( 1): 1965463. DOI: 10.1080/19490976.2021.1965463.
    [34]
    YUAN H, WU XG, WANG XC, et al. Microbial dysbiosis linked to metabolic dysfunction-associated fatty liver disease in asians: Prevotella copri promotes lipopolysaccharide biosynthesis and network instability in the Prevotella enterotype[J]. Int J Mol Sci, 2024, 25( 4): 2183. DOI: 10.3390/ijms25042183.
    [35]
    LI F, LI MW, WANG YS. Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2024, 40( 10): 2082- 2086. DOI: 10.12449/JCH241025.

    李凤, 李茂微, 王雨杉. 非酒精性脂肪肝病的治疗模式和潜在疗法[J]. 临床肝胆病杂志, 2024, 40( 10): 2082- 2086. DOI: 10.12449/JCH241025.
    [36]
    MA N, YIP R, LEWIS S, et al. Environmental exposures are important risk factors for advanced liver fibrosis in African American adults[J]. JHEP Rep, 2023, 5( 4): 100696. DOI: 10.1016/j.jhepr.2023.100696.
    [37]
    NGUYEN VH, YEO YH, ZOU B, et al. Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD[J]. J Intern Med, 2021, 289( 6): 840- 850. DOI: 10.1111/joim.13203.
    [38]
    GIAMMARINO AM, QIU H, BULSARA K, et al. Community socioeconomic deprivation predicts nonalcoholic steatohepatitis[J]. Hepatol Commun, 2022, 6( 3): 550- 560. DOI: 10.1002/hep4.1831.
    [39]
    ELANGOVAN A, SHAH R, SMITH ZL. Pharmacotherapy for obesity-trends using a population level national database[J]. Obes Surg, 2021, 31( 3): 1105- 1112. DOI: 10.1007/s11695-020-04987-2.
    [40]
    MAY M, SCHINDLER C, ENGELI S. Modern pharmacological treatment of obese patients[J]. Ther Adv Endocrinol Metab, 2020, 11: 2042018819897527. DOI: 10.1177/2042018819897527.
    [41]
    ADEJUMO AC, SAMUEL GO, ADEGBALA OM, et al. Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States[J]. Ann Gastroenterol, 2019, 32( 5): 504- 513. DOI: 10.20524/aog.2019.0402.
    [42]
    RIEMAN-KLINGLER MC, JUNG J, TESFAI K, et al. Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease[J]. Am J Biol Anthropol, 2024, 184( 4): e24979. DOI: 10.1002/ajpa.24979.
    [43]
    VERSTRAETE SG, WOJCICKI JM, PERITO ER, et al. Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003-2010[J]. Environ Health, 2018, 17( 1): 12. DOI: 10.1186/s12940-018-0356-3.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (90) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return